Barclays
CELZ icon

Barclays’s Creative Medical Technology CELZ Stock Holding History

Barclays’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78 Buy
+54
New +$117 ﹤0.01% 5213

Other funds holding CELZ

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays's CELZ Position: Q2 2026 in Review

Barclays opened a new position in Creative Medical Technology (CELZ) in Q2 2026: 54 shares worth $78. The stake represents ﹤0.01% of the portfolio and ranks #5213 among its holdings.

15 funds tracked by Wall St. Rank hold CELZ as of Q2 2026.

  • Barclays held 54 shares of Creative Medical Technology worth $78 as of Q2 2026.
  • Creative Medical Technology was a new Barclays position in Q2 2026.
  • Creative Medical Technology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5213 holding.
  • 15 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.